Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).
As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.